VNA
GNCA

Valley National Advisers’s Genocea Biosciences, Inc. GNCA Stock Holding History

Valley National Advisers’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,250
Closed -$4K – 863
2019
Q3 		$4K Buy
+1,250
New +$4.27K ﹤0.01% 622

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Valley National Advisers's GNCA Position: Q4 2019 in Review

Valley National Advisers sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2019, closing a stake of 1,250 shares — an estimated $4K sold.

Valley National Advisers first reported a position in GNCA in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 34 funds tracked by Wall St. Rank hold GNCA as of Q4 2019.

  • Valley National Advisers reported no remaining Genocea Biosciences, Inc. position as of Q4 2019 after selling out during the quarter.
  • Valley National Advisers sold 1,250 Genocea Biosciences, Inc. shares in Q4 2019, an estimated $4K.
  • Valley National Advisers first reported a position in Genocea Biosciences, Inc. in Q3 2019 and held it in 1 quarter.
  • Valley National Advisers's Genocea Biosciences, Inc. position peaked at $4K in Q3 2019.
  • 34 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2019.

Based on Valley National Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.